温阳活血中药复方对急性非ST段抬高心肌梗死患者的影响

Effect of Wenyang Huoxue Compound Prescription on Acute Non-ST Segment Elevation Myocardial Infartion Patients

目的：探讨温阳活血中药复方对急性非ST段抬高心肌梗死（NSTEMI）患者超敏C反应蛋白（hs CRP）、肌钙蛋白、血脂水平的影响。方法：收集本院收治的的NSTEMI患者72例,随机分为对照组和试验组,各36例,对照组患者给予常规的冠脉介入（PCI）治疗及常规西药治疗。试验组在此基础上应用温阳活血中药复方治疗,观察治疗前,治疗1周后两组患者hs CRP、氨基末端脑钠肽（NT-pro BNP）和肌钙蛋白T（cTnI）水平、血脂水平、心绞痛发作次数、心肌缺血时间、室性早搏次数、心肌酶学的变化及不良反应发生情况。结果：治疗后,两组患者的血清hs CRP、NT-pro BNP及cTnT水平降低,TC、LDL-C、TG水平降低,HDL-C升高,肌酸激酶同工酶（CK-MB）、肌酸激酶（CK）、天门冬氨酸转移酶（AST）及乳酸脱氢酶（LDH）水平降低,差异有统计学意义（P〈0.05）;与对照组相比,试验组临床总有效率较高（P〈0.05）,血清hs CRP、NT-pro BNP及cTnI水平较低,TC、LDL-C、TG水平较低,HDL-C较高,心绞痛发作次数、心肌缺血时间以及室性早搏次数较低,CK-MB、CK、AST以及LDH水平较低,差异有统计学意义（P〈0.05）。两组患者不良反应的发生率无明显差异（P〉0.05）。结论：温阳活血中药复方治疗能够下调NSTEMI患者hs CRP、肌钙蛋白水平,缓解炎症反应,改善心功能以及血脂水平,安全性较高,适宜临床推广应用。

Objective： To investigate the effect of Wenyang Huoxue Compound Prescription on hypersensitive C-reactive protein,troponin and blood lipid in patients with acute non-ST segment elevation myocardial infarction（NSTEMI）. Methods： A total of 72 patients of NSTEMI patients were randomly divided into control group and experiment group. The control group was given conventional coronary intervention（PCI） and routine western medicine. On the basis of this trial,the experiment group was treated more with Wenyang Huoxue Compound Prescription. The levels of hs-CRP,NT-pro BNP,c Tn I,lipid levels,angina episodes,myocardial ischemia time,number of ventricular premature beats,myocardial enzymes and the occurrence of adverse reactions were observed before and after treatment for 1 week. Results： Compared with before treatment,levels of serum hs CRP,NT-pro BNP,and c Tn T levels decreased,TC,LDL-C,TG levels decreased,HDL-C increased,creatine kinase isoenzymes（CK-MB）,and creatine levels in both groups. The levels of CK,aspartate transferase（AST） and lactate dehydrogenase（LDH） decreased significantly（P〈0. 05）. Compared with the control group,the total clinical efficacy was higher in the experimental group.（P〈0. 05） Serum hs CRP,NT-pro BNP,and c Tn I levels were lower,TC,LDL-C,TG levels were lower,HDL-C was higher,and the number of angina episodes,myocardial ischemia time,the number of ventricular premature beats were comparable lower,CK-MB,CK,AST,and LDH levels were lower,and the difference was statistically significant（P〈0. 05）. There was no significant difference in the incidence of adverse reactions between the two groups（P〉0. 05）. Conclusion： Wenyang Huoxue Compound Prescription can reduce the levels of hs-CRP and troponin in patients with NSTEMI,relieve inflammation,improve heart function and blood lipids,and has higher safety. It is suitable for clinical application.